Anti-Human/Mouse Integrin beta7 - Purified In vivo GOLD Functional Grade

Antibody Details

Product Details

Reactivity Species

Human/Mouse

Host Species

Rat

Immunogen

TK1 Cells

Product Concentration

≥ 5.0 mg/ml

Endotoxin Level

≤ 1.0 EU/mg as determined by the LAL method

Purity

≥95% monomer by analytical SEC

⋅

> 95% by SDS Page

Formulation

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.

Product Preparation

Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Storage and Handling

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Country of Origin

USA

Shipping

2-8°C

RRID

AB_2830480

Applications and Recommended Usage?
Quality Tested by Leinco

FC The suggested concentration of use for clone FIB504 antibody for staining cells in flow cytometry is ≤0.5 µg per 10⁶ cells in a volume of 100 μl or 100 μl of whole blood. Each lot of this antibody is quality control tested.

Other Applications Reported In Literature ?

B This antibody has been reported to block beta7 integrin mediated cell adhesion for In vitro and In vivo studies.
IP
CyTOF®

Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity

Clone FIB504 recognizes an epitope on human/mouse integrin β7.

Antigen Distribution

Integrin α4β7 is expressed on subsets of peripheral lymphocytes, thymocytes, and bone marrow progenitors. The αEβ7 integrin is expressed on mucosal T cells, including intraepithelial T lymphocytes (IELs) and lamina propria T cells, subsets of dendritic cells, and regulatory T cells (Tregs)⁸.

Background

Integrin β7 antibody, clone FIB504, recognizes integrin β7, a 130 kDa membrane glycoprotein of the Ig superfamily. Integrin β7 forms heterodimers with both the α4 (CD49d) and aE (CD103) integrins. α4β7 integrin is expressed on subsets of peripheral lymphocytes, thymocytes, and bone marrow progenitors^{1, 2}. It mediates adhesion to mucosal endothelial cells, promoting leukocyte transendothelial migration through interactions with mucosal addressin cell adhesion molecule-1 (MAdCAM-1)^{3, 4}. The αEβ7 integrin is expressed on mucosal T cells, including intraepithelial T lymphocytes (IELs) and lamina propria T cells^{5, 6}, subsets of dendritic cells⁷, and regulatory T cells (Tregs)8. It facilitates retention in the gut epithelial layer via interactions with E-cadherin⁹. Anti-β7 antibodies block both the homing to and retention in the gut of pathogenic T cells¹⁰ and are currently under evaluation in a phase 3 clinical trial to treat inflammatory bowel disease¹¹.

Antigen Details

Protein

Integrin Beta 7

Ligand/Receptor

CD49d/β7: VCAM-1 (CD106), MAdCAM-1 and fibronectin; CD103/β7: E-cadherin

Function

Lymphocyte adhesion, hematopoietic progenitor cells migration

PubMed

Integrin Beta 7

NCBI Gene Bank ID

16421

UniProt.org

Information on Uniprot.org

Research Area

Cell Biology

.

Immunology

.

Neuroscience

References & Citations

1. Andrew DP, et al. (1996) Eur J Immunol. 26(4):897-905
2. Murakami JL, et al. (2016) Stem Cells Dev. 25(1):18-26
3. Hu MC, et al. (1992) Proc Natl Acad Sci USA. 89(17):8254-8
4. Hamann A, et al. (1994) J Immunol. 152(7):3282-93
5. Hadley GA Higgins JM. (2014) Adv Exp Med Biol. 819:97–110
6. Farstad IN., et al. (1996) Immunology. 89:227–37
7. Jaensson E., et al. (2008) J Exp Med. 205:2139–49
8. Allez M, et al. (2002) Gastroenterology. 123(5):1516-26
9. Schön MP, et al. (1999) J Immunol. 162(11):6641-9
10. Stefanich EG, et al. (2011) Br J Pharmacol. 162(8):1855-1870
11. Smids C, et al. (2017) J Crohns Colitis. 11(4):500-508

Technical Protocols